Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out

Search

  • Advanced search
The Journal of Immunology
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons
  • Subscribe
  • My alerts
  • Log in
  • Log out
The Journal of Immunology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Follow The Journal of Immunology on Twitter
  • Follow The Journal of Immunology on RSS

Urokinase Receptor Is Necessary for Bacterial Defense against Pneumonia-Derived Septic Melioidosis by Facilitating Phagocytosis

W. Joost Wiersinga, Liesbeth M. Kager, Joppe W. R. Hovius, Gerritje J. W. van der Windt, Alex F. de Vos, Joost C. M. Meijers, Joris J. Roelofs, Arjen Dondorp, Marcel Levi, Nicholas P. Day, Sharon J. Peacock and Tom van der Poll
J Immunol March 15, 2010, 184 (6) 3079-3086; DOI: https://doi.org/10.4049/jimmunol.0901008
W. Joost Wiersinga
*Center for Infection and Immunity Amsterdam,
†Center for Experimental and Molecular Medicine,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Liesbeth M. Kager
*Center for Infection and Immunity Amsterdam,
†Center for Experimental and Molecular Medicine,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joppe W. R. Hovius
*Center for Infection and Immunity Amsterdam,
†Center for Experimental and Molecular Medicine,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerritje J. W. van der Windt
*Center for Infection and Immunity Amsterdam,
†Center for Experimental and Molecular Medicine,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alex F. de Vos
*Center for Infection and Immunity Amsterdam,
†Center for Experimental and Molecular Medicine,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joost C. M. Meijers
‡Department of Vascular Medicine, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joris J. Roelofs
§Department of Pathology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arjen Dondorp
¶Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marcel Levi
*Center for Infection and Immunity Amsterdam,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicholas P. Day
¶Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; and
‖Center for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sharon J. Peacock
¶Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; and
‖Center for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tom van der Poll
*Center for Infection and Immunity Amsterdam,
†Center for Experimental and Molecular Medicine,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Urokinase receptor (urokinase-type plasminogen activator receptor [uPAR], CD87), a GPI-anchored protein, is considered to play an important role in inflammation and fibrinolysis. The Gram-negative bacterium Burkholderia pseudomallei is able to survive and replicate within leukocytes and causes melioidosis, an important cause of pneumonia-derived community-acquired sepsis in Southeast Asia. In this study, we investigated the expression and function of uPAR both in patients with septic melioidosis and in a murine model of experimental melioidosis. uPAR mRNA and surface expression was increased in patients with septic melioidosis in/on both peripheral blood monocytes and granulocytes as well as in the pulmonary compartment during experimental pneumonia-derived melioidosis in mice. uPAR-deficient mice intranasally infected with B. pseudomallei showed an enhanced growth and dissemination of B. pseudomallei when compared with wild-type mice, corresponding with increased pulmonary and hepatic inflammation. uPAR knockout mice demonstrated significantly reduced neutrophil migration toward the pulmonary compartment after inoculation with B. pseudomallei. Further in vitro experiments showed that uPAR-deficient macrophages and granulocytes display a markedly impaired phagocytosis of B. pseudomallei. Additional studies showed that uPAR deficiency did not influence hemostatic and fibrinolytic responses during severe melioidosis. These data suggest that uPAR is crucially involved in the host defense against sepsis caused by B. pseudomallei by facilitating the migration of neutrophils toward the primary site of infection and subsequently facilitating the phagocytosis of B. pseudomallei.

Urokinase receptor (urokinase-type plasminogen activator receptor [uPAR], CD87) is a GPI-anchored protein that functions as the receptor for uPA (1). uPAR, which is expressed by a wide variety of cells, including monocytes, macrophages, and neutrophils (1, 2), has important roles in both physiological and pathological processes; in addition to its regulatory role in fibrinolysis and inflammation, it has been implicated in tumor invasion, metastasis, urinary protein loss, and the development of protective immunity in infections (1, 3–6). Importantly, uPAR has been shown to contribute to activation and mobilization of leukocytes (3, 7) and to play a protective role in murine pulmonary infection (7, 8). In humans, i.v. injection of LPS was associated with an upregulation of uPAR on circulating monocytes and granulocytes (9, 10). However, the precise role of uPAR in human sepsis is still largely undefined.

Melioidosis, caused by the Gram-negative bacillus Burkholderia pseudomallei, is an important cause of community-acquired sepsis in Southeast Asia and Northern Australia (11, 12). We recently reported that patients with melioidosis demonstrate evidence for both activation and inhibition of fibrinolysis, as reflected by concurrently elevated concentrations of tissue-type plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1), accompanied by a net increase in plasmin generation as indicated by elevated plasma concentrations of plasmin-α2–antiplasmin complexes and d-dimer (13). More than half of the cases of melioidosis habitually present with pneumonia, frequently associated with bacterial dissemination to distant sites (12, 14). Pulmonary exposure to B. pseudomallei rapidly elicits the massive recruitment of activated neutrophils but not monocytes (15, 16). In vitro models indicate that B. pseudomallei survives and replicates within neutrophils and monocytes (12, 17–19). B. pseudomallei is very capable of escaping from phagocytosis and consequent killing (12, 20). There are no data yet, however, on ways used by the host to enable effective phagocytosis of invading B. pseudomallei.

With the aim of clarifying the role of uPAR in pneumonia-derived melioidosis, we investigate in this study the expression and function of uPAR both in patients with septic melioidosis and a murine model of experimental melioidosis. Our results show that uPAR is upreg-ulated in melioidosis, and, although its in vivo role in fibrinolysis is limited, it does play a key role in bacterial clearance. This is explained by both in vitro and in vivo experiments in which we show that neutrophil recruitment and phagocytosis are uPAR-dependent mechanisms in melioidosis. Activation of uPAR and its favorable effects on antibacterial host defense represent a new host defense mechanism in melioidosis.

Materials and Methods

Human subjects

Thirty-four patients (mean age, 52 y; range, 18–86 y) with sepsis caused by B. pseudomallei and 32 healthy controls (mean age, 41 y; range, 21–59 y) from the same area were studied. All subjects were recruited prospectively at Sapprasithiprasong Hospital, Ubon Ratchathani, Thailand, in 2004. Sepsis due to melioidosis was defined as culture positivity for B. pseudomallei from any clinical sample plus a systemic inflammatory response syndrome (21). B. pseudomallei was cultured from body material from all patients: blood cultures were positive for B. pseudomallei in 21 patients (61.7%), throat swab or tracheal suction in 13 patients (38.0%), sputum in 7 patients (21.0%), pus from abscess in 7 patients (21.0%), and urine in 5 patients (14.7%). The overall patient mortality was 44%. Study design and subjects have been described in detail (22). The study was approved by both the Ministry of Public Health, Royal Government of Thailand, and the Oxford Tropical Research Ethics Committee, University of Oxford, Oxford, U.K. We obtained written informed consent from all subjects before the study.

FACS analysis

In humans, expression of uPAR and CD14 on monocytes and neutrophils in whole blood was determined with an FACSCalibur (BD Biosciences, San Jose, CA) using fluorochrome-conjugated mouse anti-human uPAR (BD Pharmingen, San Diego, CA) and CD14 Abs (BD Biosciences) in combination with the appropriate isotype control Abs. Granulocytes were identified according to their scatter pattern and monocytes according to their scatter pattern and CD14 positivity. In mice, blood and whole lung cell suspensions were obtained as described previously (16, 22). Immunostaining was performed using directly labeled Abs against GR-1 (GR-1 FITC; BD Pharmingen), F4/80 (Serotec, Oxfordshire, U.K.), and a biotin-labeled Ab against uPAR (R&D Systems, Minneapolis, MN) in combination with streptavidin-conjugated PerCP. After staining, cells were fixed in 2% paraformaldehyde. uPAR mean fluorescence intensity (MFI) was measured in the Gr-1 high (granulocytes), sidescatter low and F4/80 positive (monocytes), and sidescatter high and F4/80 positive (macrophages) gated populations. Abs were used in concentrations recommended by the manufacturer.

Quantitative real-timePCR

Leukocytes were isolated from heparinized blood using erythrocyte lysis buffer. Monocyte and granulocyte enriched populations were isolated using Polymorphprep (Axis-Shield, Dundee, U.K.) as described (22). Monocyte and granulocyte fractions were >98% pure as determined by their scatter pattern on flow cytometry. After isolation, leukocytes, monocytes, and granulocytes were dissolved in Trizol (Invitrogen, Carlsbad, CA) and stored at −80°C until used for RNA isolation. Real-time RT-PCR was performed using the LightCycler (Roche, Woerden, The Netherlands) apparatus as described (16). Gene expression is presented as a ratio of the housekeeping gene β2-microglobulin expression (23). Primers, purchased from Eurogentec, Seraing, Belgium, used for human uPAR were S606 5′-AATCCT-GGAGCTTGAAAATCT-3′ and 5′-AS875 CCACTTTTAGTACAGCAGG-AGA-3′.

Murine melioidosis

The Animal Care and Use of Committee of the University of Amsterdam approved all experiments. All mice were on a C57BL/6 background. Pathogen-free 8–10-wk-old wild-type (WT) mice were purchased from Harlan Sprague Dawley (Horst, The Netherlands). uPAR knockout (KO) mice were purchased from The Jackson Laboratory (Bar Harbor, ME) (24). Age- and sex-matched animals were used in each experiment. For the inoculum, B. pseudomallei strain 1026b, kindly provided by Dr. Don Woods (25, 26), was used and prepared as described (16, 22). Pneumonia was induced by intranasal inoculation of a 50-μl (5 × 102 CFU/50 μl) bacterial suspension. Twenty-four, 48, and 72 h postinfection, mice were sacrificed by bleeding from the inferior vena cava. Pulmonary homogenates, cell suspensions, peritoneal lavage, and bronchoalveolar lavage fluid were obtained from infected mice as described previously (16, 22, 27).

Assays

TNF-α, IFN-γ, IL-6, IL-10, and IL-12p70 were determined using a cytometric bead array multiplex assay (BD Biosciences). Myeloperoxidase (MPO; HyCult Biotechnology, Uden, The Netherlands), thrombin-antithrombin complexes (TATc; Dade Behring, Marburg, Germany), and d-dimer (Diagnostica Stago, Asnières-sur-Seine, France) were measured with commercially available ELISA kits. Plasminogen activator activity (PAA) was measured by an amidolytic assay. Briefly, diluted euglobulin-precipitated fractions of plasma were incubated with 0.30 mmol/l S-2251, 0.13 mol/l plasminogen, and 0.12 mg/ml CNBr fragments of fibrinogen (all obtained from Chromogenix, Mölndal, Sweden). Conversion of plasminogen to plasmin was detected by subsequent conversion of the chromogenic substrate S-2251 and was detected with a spectrophotometer. Results are expressed in percentage increase as compared with baseline values of normal plasma (28). Aspartate aminotransferase, alanine aminotransferase, blood urea nitrogen (urea), and creatinin were determined with commercially available kits (Sigma-Aldrich, St. Louis, MO) using a Hittachi analyzer (Boehringer Mannheim, Mannheim, Germany).

Histologic examination

Organs were harvested at indicated time points, fixed in 10% formalin, and embedded in paraffin. Four-micrometer sections were stained with H&E and analyzed by a pathologist blinded for groups. To score inflammation and damage, the entire organ surface was analyzed regarding the presence of the following: necrosis/abscess formation, interstitial inflammation, endothelialitis, bronchitis, edema, thrombus formation, and, when applicable, pleuritis (22, 29). Neutrophils were counted in six randomly chosen fields (×100 magnification) as described (30). Granulocyte staining was done as described earlier (8). Fibrin(ogen) stainings were performed as earlier described (31), after which digital images were captured of three nonoverlapping areas (×20 objective) using a DFC500 digital camera mounted on a DM5000B microscope (both from Leica Microsystems, Wetzlar, Germany). The area for positive for fibrin(ogen) was determined with Image Pro Plus software (Media Cybernetics, Silver Spring, MD) and expressed as the percentage of the total surface area.

Cell culture and stimulation

Whole blood and peritoneal macrophages from untreated uPAR KO and WT mice (n = 5–8/strain) were harvested as described (16, 22, 27). Cells and heparinized whole blood were stimulated with LPS from B. pseudomallei 1026b (22) (500 ng/ml), mitomycin C-treated (0.2 mg/ml) (Sigma-Aldrich) growth-arrested B. pseudomallei (5 × 106 CFU/ml), or RPMI 1640 medium for 16 h. Supernatants were collected and stored at −20°C until assayed.

Bacterial killing, phagocytosis, and oxidative burst

Bacterial killing of macrophages was determined as described previously (27, 32). In brief, B. pseudomallei was spun onto a monolayer of peritoneal macrophages (derived from five different mice per group), after which plates were placed at 37°C for 10 min. After washing five times with ice-cold PBS to remove extracellular bacteria, bacterial uptake after 10 min was determined by lysing the wells with sterile distilled H2O. This was designated as t = 0. RPMI 1640 was added to remaining wells, and plates were placed at 37°C for 5 and 30 min, after which cells were washed and lysed with distilled H2O. Cell lysates were plated on blood agar plates,and bacterial counts were enumerated after 16 h. Bacterial killing of macrophages was expressed as the percentage of killed bacteria in relation to t = 0. Phagocytosis was evaluated essentially as described before (27, 33). Growth-arrested B. pseudomallei was labeled with CFSE dye (Invitrogen). Peritoneal macrophages (derived from five different mice per group) were incubated with growth-arrested CFSE-labeled B. pseudomallei (2.5 × 107 CFU/ml) for 0, 15, and 60 min. Phagocytosis was stopped by placing cells on ice; thereafter, cells were washed in PBS and suspended in quenching solution (Orpegen, Heidelberg, Germany). To determine the neutrophil phagocytosis capacity, 50 μl whole blood was incubated with bacteria, after which cells were suspended in quenching solution and incubated in FACS lysis/fix solution (BD Biosciences), and neutrophils were labeled using anti–Gr-1-PE (BD Pharmingen). Phagocytosis was determined using FACS. Phagocytosis index of each sample was calculated: (MFI × % positive cells at 37°C) − (MFI × % positive cells at 4°C). The oxidative burst response of macrophages was determined using an Amplex Red kit (Invitrogen). Macrophages (1.25 × 106 cells/ml) were plated in a black 96-well plate with a clear bottom (Greiner, Alphen a/d Rijn, The Netherlands) and allowed to adhere for 2 h. Macrophages were stimulated with buffer, 1 mg/ml serum-treated zymosan (Sigma-Aldrich), or 125 × 106 heat-killed B. pseudomallei bacteria/ml in the presence of Amplex Red (0.5 μm) and HRP (1 U/ml). Fluorescence was measured with an HT Synergy platereader (Bio-Tek Instruments, Watford Herts, U.K.) using excitation/emission wavelengths of 530/580 nm. Measurements (n = 8 for both WT and KO macrophages) were performed every 2 min for 120 min. Results are depicted as relative fluorescence units.

Statistical analysis

Values are expressed as means ± SEM. Differences between groups were analyzed by Mann-Whitney U test or Kruskal-Wallis analysis with Dunn’s post hoc test where appropriate. For survival analysis, Kaplan-Meier analysis followed by log-rank test was performed. These analyses were performed using GraphPad Prism version 4.03 (GraphPad, San Diego, CA). Values of p < 0.05 were considered statistically significant.

Results

Increased uPAR expression in patients with severe melioidosis

We quantified uPAR mRNA and surface expression on both peripheral blood monocytes and granulocytes in 34 individuals with culture-proven severe melioidosis and 32 healthy controls. Patients showed profoundly elevated levels of both uPAR mRNA and cell surface expression compared with controls (Fig. 1). In addition, an overall increase in the percentage of monocytes expressing uPAR on their cell membranes was seen in patients compared with controls (97.7% ± 2.3 versus 80.1 ± 3.1%; p < 0.0001), together with a modest decline in the percentage of uPAR-positive granulocytes (74.6 ± 4.6% versus 89.9 ± 2.3%; p < 0.05). In this cohort of patients, in which the mortality rate was 44%, the levels of either cell-associated uPAR or uPAR mRNA did not differ between survivors and nonsurvivors (data not shown).

FIGURE 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1.

uPAR is upregulated in patients with severe melioidosis. Both uPAR mRNA (A, D) and uPAR cell surface (B, E) expression were strongly increased in/on both monocytes (A–C) and granulocytes (D–F) of patients (n = 34) with sepsis caused by B. pseudomallei compared with healthy controls (n = 32). C and F show representative histograms of monocyte and granulocyte uPAR expression, respectively, in a healthy control (bold line) and in a patient (filled gray area). CD87 is synonymous for uPAR. hB2M, human β2-microglobulin. **p < 0.01; ***p < 0.001.

Increased uPAR expression in the pulmonary compartment during experimental pneumonia-derived melioidosis

Because the majority of severe melioidosis cases present with pneumonia with bacterial dissemination to distant body sites (11, 12, 14), and considering the fact that it is not feasible to study uPAR expression at tissue level in patients with melioidosis, we used a murine model of pneumonia-derived melioidosis in which mice are intranasally infected with B. pseudomallei (16, 22, 34). In line with the data obtained in patients with melioidosis, 48 h postinfection mice showed an upregulation of uPAR expression on their granulocytes, monocytes (Fig. 2), and alveolar macrophages (data not shown). The increase in uPAR expression was much more pronounced at the primary site of infection, the pulmonary compartment, when compared with the systemic compartment, where only a trend toward increased uPAR expression was seen (Fig. 2).

FIGURE 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 2.

uPAR is upregulated in murine melioidosis. Cell-surface uPAR expression on blood monocytes (A), blood granulocytes (B), pulmonary monocytes (C), and pulmonary granulocytes (D) 48 h after intranasal inoculation with B. pseudomallei (gray bars) compared with saline treated control mice (white bars). n = 8 per group. *p < 0.05.

uPAR-deficient mice show an enhanced growth and dissemination of B. pseudomallei in vivo

To obtain insights into the functional role of uPAR in melioidosis, we infected uPAR KO and WT mice with B. pseudomallei and performed quantitative cultures of lung, liver, and blood at various time points thereafter. Relative to WT mice, uPAR KO mice displayed strongly increased bacterial loads in the lungs, liver, and blood at 48 and, most markedly, 72 h post intranasal infection with a lethal dose of B. pseudomallei (Fig. 3).

FIGURE 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 3.

uPAR deficiency results in an enhanced growth and dissemination of B. pseudomallei in vivo. uPAR KO mice (gray bars) demonstrate strongly increased bacterial loads at 48 and 72 h postinfection in their lungs (A), liver (B), and blood (C) compared with WT mice (white bars; n = 8 per group per time point). *p < 0.05; **p < 0.01; ***p < 0.001.

uPAR KO mice display increased late lung inflammation but decreased early neutrophil migration during melioidosis

We have previously shown that intranasal inoculation with B. pseudomallei causes significant and rapid inflammation and granulocyte, but not monocyte, recruitment toward the lung (16). To further evaluate the role of uPAR in antibacterial defense against B. pseudomallei, pulmonary inflammation and granulocyte recruitment into lung tissue were assessed. Consistent with the observed enhanced growth of B. pseudomallei in uPAR KO mice, uPAR KO mice showed increased late pulmonary inflammation, which was characterized by significantly more inflammation, pleuritis, peribronchial inflammation, edema, and endothelialitis when compared with control mice (Fig. 4). Strikingly, however, early pulmonary neutrophil recruitment was impaired in uPAR KO mice in response to intranasal infection with B. pseudomallei as visualized by Ly-6 staining and confirmed by lower MPO concentrations in lung homogenates at 24 h postinfection (Fig. 5).

FIGURE 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 4.

Increased late lung inflammation in uPAR KO mice infected with B. pseudomallei. Representative lung histology of WT (A) and uPAR KO mice (B) showing significantly more inflammation, pleuritis, peribronchial inflammation, edema, and necrosis 72 h after intranasal infection with 5 × 102 CFU B. pseudomallei in the uPAR KO mice compared with compared with WT controls (H&E, original magnification ×100). C shows the corresponding pathology scores (means ± SEM) calculated as described in Materials and Methods. White bars represent WT mice; gray bars represent uPAR KO mice (n = 8 per group at each time point). *p < 0.05.

FIGURE 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 5.

Decreased early granulocyte migration in uPAR KO mice infected with B. pseudomallei. Representative of Ly6G-immunostaining (original magnification ×400) for granulocytes of WT (A) and uPAR KO mice (B) showing significantly less neutrophil influx at 24 h postinoculation in uPAR KO mice when compared with WT mice (C), corresponding with decreased early MPO activity levels in lung tissues in uPAR KO mice (D). White bars represent WT mice; gray bars represent uPAR KO mice (n = 8 per group at each time point). Number of granulocytes expressed as mean number of granulocytes per field ± SEM. *p < 0.05; **p < 0.01.

Limited effect of uPAR deficiency on cytokine response, distant organ injury, and survival

Because the localized production of cytokines is an important part of host defense against infection (35), we measured the concentrations of these mediators in the pulmonary and systemic compartment. Overall, uPAR deficiency did not have a major impact on cytokine concentrations postinfection with B. pseudomallei (Table I). The most notable difference was a mean 50% reduction in TNF-α levels in lung homogenates of uPAR KO mice at 24 h postinfection (p < 0.05 versus WT mice), but not in plasma and/or later time points. At 72 h postinfection, cytokine levels tended to be higher in uPAR KO mice, most likely reflecting the increased bacterial loads and lung inflammation, but probably due to a relatively large interindividual variation, the difference with WT mice only reached statistical significance for lung IL-6 and plasma IL-10 concentrations. Furthermore, in line with the observed increased bacterial loads in the liver, uPAR KO mice showed significantly more hepatic inflammation after 72 h compared with WT mice postinoculation with B. pseudomallei (mean histological score 4.7 ± 0.5 versus 2.1 ± 0.4; p < 0.01). Consistent with these pathology data, the plasma levels of aspartate aminotransferase (1284 ± 457 versus 183 ± 45; p < 0.05) and alanine aminotransferase (814 ± 351 versus 86 ± 21; p < 0.05) were higher in uPAR KO mice 72 h postinfection compared with WT mice, reflecting increased hepatocellular injury in these animals. Additionally, all mice showed evidence of renal failure, as indicated by elevated plasma concentrations of urea (12.5 ± 4.4 versus 7.5 ± 0.6; not significant) and creatinine (19.2 ± 9.3 versus 8.5 ± 0.5; not significant); however, no differences were seen between uPAR KO and WT mice. As a last part of our in vivo experiments, we performed a survival experiment for which we inoculated WT and uPAR KO mice with B. pseudomallei and monitored them for 14 d. Infection with the bacterial dose also employed in the experiments described above caused lethality in 12 out of 12 WT mice and 11 out of 12 uPAR KO mice (Fig. 6). Remarkably, mortality was slightly but statistically significantly delayed in uPAR KO mice (p < 0.05; Fig. 6).

View this table:
  • View inline
  • View popup
Table I. Cytokine response in lung homogenates and plasma of WT and uPAR KO mice during melioidosis
FIGURE 6.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 6.

Effect of uPAR deficiency on survival of mice infected with B. pseudomallei. WT and uPAR KO mice were inoculated with 5 × 102 CFU of B. pseudomallei intranasally. n = 12 mice per group. p < 0.05.

Contribution of uPAR toward cellular responsiveness to B. pseudomallei in vitro

To obtain additional insights into the function of uPAR in the host defense against B. pseudomallei, we started to analyze the requirement of uPAR signaling upon first encounter between the bacterium and the host. Therefore, we tested the cytokine production capacity of macrophages and whole blood harvested from WT and uPAR KO mice upon stimulation with B. pseudomallei LPS or growth-arrested B. pseudomallei (E:T ratio 1:10). Whole blood obtained from uPAR KO mice released equal amounts of TNF-α, IFN-γ, IL-6, IL-10, and IL-12p70 upon stimulation with B. pseudomallei in vitro as compared with WT mice (Table II). These data suggest that uPAR does not contribute to cellular responsiveness to B. pseudomallei in whole blood in vitro. Of interest, uPAR-deficient macrophages released more TNF-α, IL-6, and IL-10 compared with WT cells upon exposure to B. pseudomallei (Table II).

View this table:
  • View inline
  • View popup
Table II. Cytokine production from blood and peritoneal macrophages harvested from WT and uPAR KO upon in vitro stimulation with B. pseudomallei

uPAR deficiency does not influence hemostatic and fibrinolytic responses during severe melioidosis

Because uPAR is thought to play a regulatory role in fibrinolysis (1, 6), we measured pulmonary TATc, d-dimer, PAA, and fibrin levels in both WT and uPAR KO mice post intranasal inoculation with B. pseudomallei. No differences in thrombin generation, as reflected by TATc plasma levels between WT and uPAR KO mice, were seen (Fig. 7). To investigate whether the upregulated uPAR expression influenced the fibrinolytic activity, we measured d-dimer and PAA levels. No differences were observed in d-dimer and PAA levels between uPAR KO and WT mice (Fig. 7). Finally, measurement of the extent of fibrin deposition in lung tissue showed increased fibrin accumulation postinfection, but again, no differences between uPAR KO and WT mice (Fig. 7). Together, these data do not support a major role of uPAR in fibrinolysis and coagulation during melioidosis.

FIGURE 7.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 7.

uPAR deficiency does not influence pulmonary fibrinolytic activity during melioidosis. No differences were seen in pulmonary TATc (A), d-dimer (B), and PAA (C) levels between WT (white bars) and uPAR KO (gray bars) mice 72 h after intranasal inoculation with 5 × 102 CFU B. pseudomallei. Representative fibrin(ogen) immunostaining of lung tissue of infected WT (D) and uPAR KO (E) mice. Original magnification ×20. Graphical representation of the percentage of the total area with positive fibrin(ogen) staining (F) shows no difference between WT and uPAR KO mice. Data represent mean ± SEM. n = 8 per group.

Impaired phagocytosis of B. pseudomallei in uPAR-deficient macrophages and granulocytes

The experiments described above established that uPAR KO display a diminished antibacterial defense toward B. pseudomallei infection, characterized by increased bacterial loads and accompanied by diminished early recruitment of neutrophils to the primary site of infection and reduced neutrophil MPO levels. The early host response to infection is characterized by a coordinated series of effector functions that include the generation of reactive oxygen species, such as reactive oxygen species and phagocytosis. We found that the basal production of oxidative products in unchallenged macrophages is similar in WT and uPAR-deficient cells (Fig. 8). Similarly, upon activation with B. pseudomallei, uPAR-deficient macrophages displayed an unaltered ability to produce an oxidative burst when compared with WT cells (Fig. 8). We next wished to determine whether uPAR contributes to phagocytosis and/or killing of B. pseudomallei. No difference in the killing capacity between WT and uPAR KO peritoneal macrophages was observed (Fig. 8). However, both uPAR KO macrophages and uPAR KO granulocytes demonstrated a markedly diminished capacity to phagocytose B. pseudomallei (Fig. 8). Taken together, the observed impairment of bacterial clearance in uPAR KO mice can be explained by both a reduction of early neutrophil recruitment and a diminished phagocytosis capacity of these recruited uPAR-deficient immune cells.

FIGURE 8.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 8.

Impaired phagocytosis of B. pseudomallei in uPAR-deficient cells. A, Killing capacity of macrophages are shown as percentage of killed B. pseudomallei compared with t = 0. B, Respiratory burst, depicted as relative fluorescence units, upon activation with B. pseudomallei of WT and uPAR-deficient macrophages. Macrophages (C) and peripheral blood neutrophils (D) were incubated at 37°C with CFSE-labeled growth-arrested B. pseudomallei (1 × 107 CFU/ml), after which time-dependent phagocytosis was quantified (see Materials and Methods). Data are mean ± SEM. n = 5–8 per mouse strain. Open rounds represent WT cells; black squares represent uPAR KO mice. *p < 0.05; **p < 0.01.

Discussion

In this study, we show that uPAR is upregulated in severe melioidosis and plays a major role in the antibacterial innate immune response. During melioidosis, uPAR contributes to the recruitment of neutrophils to the primary site of infection and the capacity of neutrophils to phagocytose B. pseudomallei. As a consequence, uPAR KO mice displayed a markedly impaired clearance of B. pseudomallei in the pulmonary and systemic compartment upon intranasal infection together with increased lung and liver inflammation. uPAR did not impact on the fibrinolytic response to infection with B. pseudomallei. These data are the first to describe a role for uPAR in melioidosis and further add to our understanding of how infection with this facultative intracellular organism can lead to a full-blown septic illness.

Our study is the first to provide insights into the expression of both mRNA and protein cell surface uPAR expression in a cohort of patients with sepsis. In blood samples obtained from 34 prospectively enrolled patients with sepsis caused by B. pseudomallei, we showed that the increased uPAR mRNA expression is accompanied by enhanced uPAR surface expression on both monocytes and granulocytes. Because we were also interested in uPAR expression at the primary infection site and given the fact that pneumonia with bacterial dissemination to distant body sites is a common presentation of human melioidosis (11, 12, 14), we made use of a mouse model of melioidosis in which mice are intranasally infected with a lethal dose of B. pseudomallei (16, 22, 34). By doing so we were able to demonstrate increased expression of uPAR on both monocytes and granulocytes at the primary place of infection. These data are in accordance with previous data showing an increased release of uPAR in both plasma and urine of patients with urosepsis (36) and increased uPAR cell surface expression on monocytes of healthy volunteers injected with endotoxin (9, 10).

One of the most important components of the initial innate immune response in the lung against bacterial infection is the vigorous recruitment of neutrophils into pulmonary tissue and airspaces (37, 38). uPAR has been shown to play a key role in both neutrophil migration and activation (3, 7, 39). uPAR can facilitate cell migration in two ways: first, after binding to uPA, it facilitates the generation of plasmin at the cell surface, resulting in degradation of the extracellular matrix and induction of cell migration (1, 3); second, uPAR causes the activation and mobilization of leukocytes through interaction with β2-integrins, most notably CD11b/CD18 (3, 7). In the event of critical illness due to invasion of pathogens, uPAR has been shown to be important in the recruitment of leukocytes toward the primary site of infection in pneumococcal meningitis (40) and both Pseudomonas aeruginosa and pneumococcal pneumonia (7, 8). We now underwrite these earlier reports by showing that uPAR KO mice have an impaired host defense against B. pseudomallei as indicated by increased bacterial outgrowth and increased organ inflammation accompanied by a reduced early neutrophil migration toward the primary site of infection. This fully underscores the emerging insight that neutrophils play a vital role in host defense against B. pseudomallei (15). One has to recall, however, that epithelial and certain serosal cells are also known to express uPAR; therefore, in this context, one cannot rule out a potential important role for these cells during the initial immune response against B. pseudomallei (1). This notion is underscored by the finding that the epithelium is a known site of replication for B. pseudomallei (12, 41).

Our results showing a markedly impaired host defense in mice lacking uPAR after inoculation with B. pseudomallei can be explained not only by a diminished neutrophil recruitment toward the pulmonary compartment but also by the finding that uPAR is crucially involved in phagocytosis of B. pseudomallei. Because B. pseudomallei is a very virulent and facultative intracellular organism (12, 17–19), effective killing and phagocytosis are of paramount important during melioidosis. We and others (39, 42) have previously reported on the potential role of uPAR in the phagocytosis of Escherichia coli and P. aeruginosa. We now extend these findings by showing that uPAR is necessary for effective phagocytosis of B. pseudomallei by both macrophages and neutrophils. This newly described mechanism provides new insights into how the immune system is capable of mounting an effective host response against B. pseudomallei. We did not observe any difference in the killing capacity between WT and uPAR-deficient macrophages. A limitation of our current study is the fact that we do currently not have a reliable and reproducible neutrophil killing assay. Furthermore, it remains to be studied if the impaired phagocytosis observed in uPAR-deficient cells is caused by signaling deficits in the uPAR KO leukocytes. In this respect, it is of interest that uPAR is upstream of myeloid Scr kinases, which are known to play a pivotal role in phagocytosis (1, 43, 44). Interestingly, uPAR does not play a direct role in the killing of B. pseudomallei nor in the induction of oxidative burst. Furthermore, in preliminary experiments, we were not able to show a direct interaction between uPAR and B. pseudomallei (data not shown), suggesting the existence of additional important mediators in this uPAR phagocytosis pathway. Of interest, the observed modest survival advantage of uPAR KO mice could indicate that the role of uPAR changes in time during the host defense against B. pseudomallei from an early protective role toward a possible detrimental role later on during the overwhelming septic response. Further studies are warranted to assess whether uPAR plays a protective role in less severe models of melioidosis (i.e., using infectious doses that are not associated with almost 100% lethality).

Our study not only demonstrates the important role of uPAR in neutrophil migration and phagocytosis during melioidosis but also reveals the relative unimportance of uPAR in the fibrinolytic response during sepsis caused by B. pseudomallei. In patients with melioidosis, we have recently shown that the fibrinolytic system is both activated and inhibited as reflected by elevated concentrations of tPA, PAI-1, plasmin-antiplasmin complex, and d-dimer (13). Our current data argue against a major role of uPAR in fibrinolysis because there were no differences in d-dimer and PAA expression levels between uPAR KO and WT mice during experimental melioidosis. Moreover, fibrin deposition was equal in both mice strains postinfection. Interestingly, these data are in line with previous investigations (3). For instance, fibrin deposits were only found in the livers of adult mice with a dual deficiency in uPAR and tPA but not in uPAR KO mice (45). In animal models of lung injury and septic shock, reduced uPA-mediated proteolysis correlated with excessive fibrin deposition, suggesting that uPA facilitates fibrinolysis by a uPAR-independent mechanism (3, 46, 47). Clearly, the role of the fibrinolytic system in the host defense against B. pseudomallei remains to be elucidated. Studies making use of uPA-, tPA-, and PAI-1–deficient animals are underway in our laboratory.

In conclusion, our data suggest that uPAR is crucially involved in the host defense against B. pseudomallei by facilitating the migration of neutrophils toward the primary site of infection and subsequently facilitating the phagocytosis of B. pseudomallei. Activation of uPAR and its favorable effects on antibacterial host defense represent a new host defense mechanism in melioidosis. Manipulation of uPAR expression or function may be a potential target for immunomodulation in septic melioidosis.

Acknowledgments

We are grateful to Joost Daalhuisen, Marieke ten Brink, and Jennie Pater for expert technical assistance.

Disclosures The authors have no financial conflicts of interest.

Footnotes

  • This work was supported by the Dutch Foundation for Tropical Research.

  • Abbreviations used in this paper:

    hB2M
    human β2-microglobulin
    KO
    knockout
    MFI
    mean fluorescence intensity
    MPO
    myeloperoxidase
    PAA
    plasminogen activator activity
    PAI-1
    plasminogen activator inhibitor-1
    TATc
    thrombin-antithrombin complex
    tPA
    tissue-type plasminogen activator
    uPAR
    urokinase-type plasminogen activator receptor
    WT
    wild-type.

  • Received March 30, 2009.
  • Accepted January 12, 2010.
  • Copyright © 2010 by The American Association of Immunologists, Inc.

References

  1. ↵
    1. Blasi F.,
    2. P. Carmeliet
    . 2002. uPAR: a versatile signalling orchestrator. Nat. Rev. Mol. Cell Biol. 3: 932–943.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Plesner T.,
    2. N. Behrendt,
    3. M. Ploug
    . 1997. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR. Stem Cells 15: 398–408.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Mondino A.,
    2. F. Blasi
    . 2004. uPA and uPAR in fibrinolysis, immunity and pathology. Trends Immunol. 25: 450–455.
    OpenUrlCrossRefPubMed
    1. Bergmann S.,
    2. S. Hammerschmidt
    . 2007. Fibrinolysis and host response in bacterial infections. Thromb. Haemost. 98: 512–520.
    OpenUrlPubMed
    1. Wei C.,
    2. C. C. Möller,
    3. M. M. Altintas,
    4. J. Li,
    5. K. Schwarz,
    6. S. Zacchigna,
    7. L. Xie,
    8. A. Henger,
    9. H. Schmid,
    10. M. P. Rastaldi,
    11. et al
    . 2008. Modification of kidney barrier function by the urokinase receptor. Nat. Med. 14: 55–63.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Idell S.
    2003. Coagulation, fibrinolysis, and fibrin deposition in acute lung injury. Crit. Care Med. 31: (4 Suppl)S213–S220.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Gyetko M. R.,
    2. S. Sud,
    3. T. Kendall,
    4. J. A. Fuller,
    5. M. W. Newstead,
    6. T. J. Standiford
    . 2000. Urokinase receptor-deficient mice have impaired neutrophil recruitment in response to pulmonary Pseudomonas aeruginosa infection. J. Immunol. 165: 1513–1519.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Rijneveld A. W.,
    2. M. Levi,
    3. S. Florquin,
    4. P. Speelman,
    5. P. Carmeliet,
    6. T. van Der Poll
    . 2002. Urokinase receptor is necessary for adequate host defense against pneumococcal pneumonia. J. Immunol. 168: 3507–3511.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Dekkers P. E.,
    2. T. ten Hove,
    3. A. A. te Velde,
    4. S. J. van Deventer,
    5. T. van Der Poll
    . 2000. Upregulation of monocyte urokinase plasminogen activator receptor during human endotoxemia. Infect. Immun. 68: 2156–2160.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Juffermans N. P.,
    2. P. E. Dekkers,
    3. A. Verbon,
    4. P. Speelman,
    5. S. J. van Deventer,
    6. T. van der Poll
    . 2001. Concurrent upregulation of urokinase plasminogen activator receptor and CD11b during tuberculosis and experimental endotoxemia. Infect. Immun. 69: 5182–5185.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. White N. J.
    2003. Melioidosis. Lancet 361: 1715–1722.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Wiersinga W. J.,
    2. T. van der Poll,
    3. N. J. White,
    4. N. P. Day,
    5. S. J. Peacock
    . 2006. Melioidosis: insights into the pathogenicity of Burkholderia pseudomallei. Nat. Rev. Microbiol. 4: 272–282.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Wiersinga W. J.,
    2. J. C. Meijers,
    3. M. Levi,
    4. C. Van ’t Veer,
    5. N. P. Day,
    6. S. J. Peacock,
    7. T. van der Poll
    . 2008. Activation of coagulation with concurrent impairment of anticoagulant mechanisms correlates with a poor outcome in severe melioidosis. J. Thromb. Haemost. 6: 32–39.
    OpenUrlPubMed
  12. ↵
    1. Currie B. J.
    2003. Melioidosis: an important cause of pneumonia in residents of and travellers returned from endemic regions. Eur. Respir. J. 22: 542–550.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Easton A.,
    2. A. Haque,
    3. K. Chu,
    4. R. Lukaszewski,
    5. G. J. Bancroft
    . 2007. A critical role for neutrophils in resistance to experimental infection with Burkholderia pseudomallei. J. Infect. Dis. 195: 99–107.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Wiersinga W. J.,
    2. C. T. Veer,
    3. C. W. Wieland,
    4. S. Gibot,
    5. B. Hooibrink,
    6. N. P. Day,
    7. S. J. Peacock,
    8. T. van der Poll
    . 2007. Expression profile and function of triggering receptor expressed on myeloid cells-1 during melioidosis. J. Infect. Dis. 196: 1707–1716.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Jones A. L.,
    2. T. J. Beveridge,
    3. D. E. Woods
    . 1996. Intracellular survival of Burkholderia pseudomallei. Infect. Immun. 64: 782–790.
    OpenUrlAbstract/FREE Full Text
    1. Egan A. M.,
    2. D. L. Gordon
    . 1996. Burkholderia pseudomallei activates complement and is ingested but not killed by polymorphonuclear leukocytes. Infect. Immun. 64: 4952–4959.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Breitbach K.,
    2. K. Rottner,
    3. S. Klocke,
    4. M. Rohde,
    5. A. Jenzora,
    6. J. Wehland,
    7. I. Steinmetz
    . 2003. Actin-based motility of Burkholderia pseudomallei involves the Arp 2/3 complex, but not N-WASP and Ena/VASP proteins. Cell. Microbiol. 5: 385–393.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Stevens M. P.,
    2. M. W. Wood,
    3. L. A. Taylor,
    4. P. Monaghan,
    5. P. Hawes,
    6. P. W. Jones,
    7. T. S. Wallis,
    8. E. E. Galyov
    . 2002. An Inv/Mxi-Spa-like type III protein secretion system in Burkholderia pseudomallei modulates intracellular behaviour of the pathogen. Mol. Microbiol. 46: 649–659.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Levy M. M.,
    2. M. P. Fink,
    3. J. C. Marshall,
    4. E. Abraham,
    5. D. Angus,
    6. D. Cook,
    7. J. Cohen,
    8. S. M. Opal,
    9. J. L. Vincent,
    10. G. Ramsay,
    11. SCCM/ESICM/ACCP/ATS/SIS
    . 2003. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit. Care Med. 31: 1250–1256.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Wiersinga W. J.,
    2. C. W. Wieland,
    3. M. C. Dessing,
    4. N. Chantratita,
    5. A. C. Cheng,
    6. D. Limmathurotsakul,
    7. W. Chierakul,
    8. M. Leendertse,
    9. S. Florquin,
    10. A. F. de Vos,
    11. et al
    . 2007. Toll-like receptor 2 impairs host defense in gram-negative sepsis caused by Burkholderia pseudomallei (Melioidosis). PLoS Med. 4: e248.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Lupberger J.,
    2. K. A. Kreuzer,
    3. G. Baskaynak,
    4. U. R. Peters,
    5. P. le Coutre,
    6. C. A. Schmidt
    . 2002. Quantitative analysis of beta-actin, beta-2-microglobulin and porphobilinogen deaminase mRNA and their comparison as control transcripts for RT-PCR. Mol. Cell. Probes 16: 25–30.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Dewerchin M.,
    2. A. V. Nuffelen,
    3. G. Wallays,
    4. A. Bouché,
    5. L. Moons,
    6. P. Carmeliet,
    7. R. C. Mulligan,
    8. D. Collen
    . 1996. Generation and characterization of urokinase receptor-deficient mice. J. Clin. Invest. 97: 870–878.
    OpenUrlCrossRefPubMed
  22. ↵
    1. DeShazer D.
    2004. Genomic diversity of Burkholderia pseudomallei clinical isolates: subtractive hybridization reveals a Burkholderia mallei-specific prophage in B. pseudomallei 1026b. J. Bacteriol. 186: 3938–3950.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Jeddeloh J. A.,
    2. D. L. Fritz,
    3. D. M. Waag,
    4. J. M. Hartings,
    5. G. P. Andrews
    . 2003. Biodefense-driven murine model of pneumonic melioidosis. Infect. Immun. 71: 584–587.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. Knapp S.,
    2. U. Matt,
    3. N. Leitinger,
    4. T. van der Poll
    . 2007. Oxidized phospholipids inhibit phagocytosis and impair outcome in gram-negative sepsis in vivo. J. Immunol. 178: 993–1001.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Verheijen J. H.,
    2. E. Mullaart,
    3. G. T. Chang,
    4. C. Kluft,
    5. G. Wijngaards
    . 1982. A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma. Thromb. Haemost. 48: 266–269.
    OpenUrlPubMed
  26. ↵
    1. Wiersinga W. J.,
    2. A. F. de Vos,
    3. R. de Beer,
    4. C. W. Wieland,
    5. J. J. Roelofs,
    6. D. E. Woods,
    7. T. van der Poll
    . 2008. Inflammation patterns induced by different Burkholderia species in mice. Cell. Microbiol. 10: 81–87.
    OpenUrlPubMed
  27. ↵
    1. Roelofs J. J.,
    2. K. M. Rouschop,
    3. J. C. Leemans,
    4. N. Claessen,
    5. A. M. de Boer,
    6. W. M. Frederiks,
    7. H. R. Lijnen,
    8. J. J. Weening,
    9. S. Florquin
    . 2006. Tissue-type plasminogen activator modulates inflammatory responses and renal function in ischemia reperfusion injury. J. Am. Soc. Nephrol. 17: 131–140.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    1. Rijneveld A. W.,
    2. S. Weijer,
    3. S. Florquin,
    4. C. T. Esmon,
    5. J. C. Meijers,
    6. P. Speelman,
    7. P. H. Reitsma,
    8. H. Ten Cate,
    9. T. van der Poll
    . 2004. Thrombomodulin mutant mice with a strongly reduced capacity to generate activated protein C have an unaltered pulmonary immune response to respiratory pathogens and lipopolysaccharide. Blood 103: 1702–1709.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. Blander J. M.,
    2. R. Medzhitov
    . 2004. Regulation of phagosome maturation by signals from toll-like receptors. Science 304: 1014–1018.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Wan C. P.,
    2. C. S. Park,
    3. B. H. Lau
    . 1993. A rapid and simple microfluorometric phagocytosis assay. J. Immunol. Methods 162: 1–7.
    OpenUrlCrossRefPubMed
  31. ↵
    1. Wiersinga W. J.,
    2. A. F. de Vos,
    3. R. de Beer,
    4. C. W. Wieland,
    5. J. J. Roelofs,
    6. D. E. Woods,
    7. T. van der Poll
    . 2008. Inflammation patterns induced by different Burkholderia species in mice. Cell Microbiol 10: 81–87.
    OpenUrlPubMed
  32. ↵
    1. Strieter R. M.,
    2. J. A. Belperio,
    3. M. P. Keane
    . 2002. Cytokines in innate host defense in the lung. J. Clin. Invest. 109: 699–705.
    OpenUrlCrossRefPubMed
  33. ↵
    1. Florquin S.,
    2. J. G. van den Berg,
    3. D. P. Olszyna,
    4. N. Claessen,
    5. S. M. Opal,
    6. J. J. Weening,
    7. T. van der Poll
    . 2001. Release of urokinase plasminogen activator receptor during urosepsis and endotoxemia. Kidney Int. 59: 2054–2061.
    OpenUrlCrossRefPubMed
  34. ↵
    1. Wagner J. G.,
    2. R. A. Roth
    . 2000. Neutrophil migration mechanisms, with an emphasis on the pulmonary vasculature. Pharmacol. Rev. 52: 349–374.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. Craig A.,
    2. J. Mai,
    3. S. Cai,
    4. S. Jeyaseelan
    . 2009. Neutrophil recruitment to the lungs during bacterial pneumonia. Infect. Immun. 77: 568–575.
    OpenUrlFREE Full Text
  36. ↵
    1. Gyetko M. R.,
    2. D. Aizenberg,
    3. L. Mayo-Bond
    . 2004. Urokinase-deficient and urokinase receptor-deficient mice have impaired neutrophil antimicrobial activation in vitro. J. Leukoc. Biol. 76: 648–656.
    OpenUrlAbstract/FREE Full Text
  37. ↵
    1. Paul R.,
    2. F. Winkler,
    3. I. Bayerlein,
    4. B. Popp,
    5. H. W. Pfister,
    6. U. Koedel
    . 2005. Urokinase-type plasminogen activator receptor regulates leukocyte recruitment during experimental pneumococcal meningitis. J. Infect. Dis. 191: 776–782.
    OpenUrlAbstract/FREE Full Text
  38. ↵
    1. Kespichayawattana W.,
    2. P. Intachote,
    3. P. Utaisincharoen,
    4. S. Sirisinha
    . 2004. Virulent Burkholderia pseudomallei is more efficient than avirulent Burkholderia thailandensis in invasion of and adherence to cultured human epithelial cells. Microb. Pathog. 36: 287–292.
    OpenUrlCrossRefPubMed
  39. ↵
    1. Roelofs J. J.,
    2. K. M. Rouschop,
    3. G. J. Teske,
    4. N. Claessen,
    5. J. J. Weening,
    6. T. van der Poll,
    7. S. Florquin
    . 2006. The urokinase plasminogen activator receptor is crucially involved in host defense during acute pyelonephritis. Kidney Int. 70: 1942–1947.
    OpenUrlPubMed
  40. ↵
    1. D’Alessio S.,
    2. F. Blasi
    . 2009. The urokinase receptor as an entertainer of signal transduction. Front. Biosci. 14: 4575–4587.
    OpenUrlPubMed
  41. ↵
    1. Paul R.,
    2. B. Obermaier,
    3. J. Van Ziffle,
    4. B. Angele,
    5. H. W. Pfister,
    6. C. A. Lowell,
    7. U. Koedel
    . 2008. Myeloid Src kinases regulate phagocytosis and oxidative burst in pneumococcal meningitis by activating NADPH oxidase. J. Leukoc. Biol. 84: 1141–1150.
    OpenUrlAbstract/FREE Full Text
  42. ↵
    1. Bugge T. H.,
    2. M. J. Flick,
    3. M. J. Danton,
    4. C. C. Daugherty,
    5. J. Romer,
    6. K. Dano,
    7. P. Carmeliet,
    8. D. Collen,
    9. J. L. Degen
    . 1996. Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc. Natl. Acad. Sci. USA 93: 5899–5904.
    OpenUrlAbstract/FREE Full Text
  43. ↵
    1. Yamamoto K.,
    2. D. J. Loskutoff
    . 1996. Fibrin deposition in tissues from endotoxin-treated mice correlates with decreases in the expression of urokinase-type but not tissue-type plasminogen activator. J. Clin. Invest. 97: 2440–2451.
    OpenUrlCrossRefPubMed
  44. ↵
    1. Barazzone C.,
    2. D. Belin,
    3. P. F. Piguet,
    4. J. D. Vassalli,
    5. A. P. Sappino
    . 1996. Plasminogen activator inhibitor-1 in acute hyperoxic mouse lung injury. J. Clin. Invest. 98: 2666–2673.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

The Journal of Immunology: 184 (6)
The Journal of Immunology
Vol. 184, Issue 6
15 Mar 2010
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Advertising (PDF)
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Immunology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Urokinase Receptor Is Necessary for Bacterial Defense against Pneumonia-Derived Septic Melioidosis by Facilitating Phagocytosis
(Your Name) has forwarded a page to you from The Journal of Immunology
(Your Name) thought you would like to see this page from the The Journal of Immunology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Urokinase Receptor Is Necessary for Bacterial Defense against Pneumonia-Derived Septic Melioidosis by Facilitating Phagocytosis
W. Joost Wiersinga, Liesbeth M. Kager, Joppe W. R. Hovius, Gerritje J. W. van der Windt, Alex F. de Vos, Joost C. M. Meijers, Joris J. Roelofs, Arjen Dondorp, Marcel Levi, Nicholas P. Day, Sharon J. Peacock, Tom van der Poll
The Journal of Immunology March 15, 2010, 184 (6) 3079-3086; DOI: 10.4049/jimmunol.0901008

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Urokinase Receptor Is Necessary for Bacterial Defense against Pneumonia-Derived Septic Melioidosis by Facilitating Phagocytosis
W. Joost Wiersinga, Liesbeth M. Kager, Joppe W. R. Hovius, Gerritje J. W. van der Windt, Alex F. de Vos, Joost C. M. Meijers, Joris J. Roelofs, Arjen Dondorp, Marcel Levi, Nicholas P. Day, Sharon J. Peacock, Tom van der Poll
The Journal of Immunology March 15, 2010, 184 (6) 3079-3086; DOI: 10.4049/jimmunol.0901008
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Early Self-Regulatory Mechanisms Control the Magnitude of CD8+ T Cell Responses Against Liver Stages of Murine Malaria
  • Sublethal Hyperoxia Impairs Pulmonary Innate Immunity
  • Dependence of IL-4, IL-13, and Nematode-Induced Alterations in Murine Small Intestinal Smooth Muscle Contractility on Stat6 and Enteric Nerves
Show more HOST DEFENSE

Similar Articles

Navigate

  • Home
  • Current Issue
  • Next in The JI
  • Archive
  • Brief Reviews
  • Pillars of Immunology
  • Translating Immunology

For Authors

  • Submit a Manuscript
  • Instructions for Authors
  • About the Journal
  • Journal Policies
  • Editors

General Information

  • Advertisers
  • Subscribers
  • Rights and Permissions
  • Accessibility Statement
  • FAR 889
  • Privacy Policy
  • Disclaimer

Journal Services

  • Email Alerts
  • RSS Feeds
  • ImmunoCasts
  • Twitter

Copyright © 2022 by The American Association of Immunologists, Inc.

Print ISSN 0022-1767        Online ISSN 1550-6606